📊 EDIT Key Takeaways
Is EDIT a Good Investment? Thesis Analysis
Editas Medicine demonstrates severe fundamental deterioration with massive operating losses (-$160M on $40.5M revenue) and negative free cash flow (-$165.8M), indicating the company is burning through cash at an unsustainable rate. Despite revenue growth of 25.4% YoY, profitability metrics are deeply negative with -395% net margin, and the company is consuming its cash reserves ($146.6M) to fund ongoing losses, leaving limited runway for R&D execution.
Why Buy EDIT? Key Strengths
- Strong liquidity position with $146.6M in cash and 3.54x current ratio providing near-term operational flexibility
- Revenue growth of 25.4% YoY shows commercial traction in their therapeutic programs
- Improvement in net loss by 32.5% YoY suggests operational efficiency gains are beginning to materialize
EDIT Investment Risks to Consider
- Unsustainable cash burn rate of -$165.8M in free cash flow with only ~11 months of cash runway at current burn rate
- Pre-commercial or early-stage company with -$160M operating loss and -395% net margin indicating no path to profitability in near-term
- High leverage with 1.96x debt-to-equity ratio limits financial flexibility and increases refinancing risk as cash depletes
- Gross margin data unavailable, preventing assessment of unit economics and cost structure sustainability
Key Metrics to Watch
- Operating cash burn rate and remaining cash runway until profitability or capital raise needed
- Revenue growth acceleration and gross margin achievement as products move toward scale
- Clinical trial progress and regulatory milestones that could validate long-term commercial potential
EDIT Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.54x current ratio provides a solid financial cushion.
EDIT Profitability Ratios
EDIT vs Healthcare Sector
How Editas Medicine, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is EDIT Overvalued or Undervalued?
Based on fundamental analysis, Editas Medicine, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
EDIT Balance Sheet & Liquidity
EDIT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Editas Medicine, Inc.'s revenue has declined by 55% over the 5-year period, indicating business contraction. The most recent EPS of $-2.88 indicates the company is currently unprofitable.
EDIT Growth Metrics (YoY)
EDIT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $61.0K | -$25.1M | $-0.28 |
| Q2 2025 | $513.0K | -$53.2M | $-0.63 |
| Q1 2025 | $1.1M | -$62.0M | $-0.76 |
| Q3 2024 | $61.0K | -$40.3M | $-0.55 |
| Q2 2024 | $513.0K | -$40.3M | $-0.56 |
| Q1 2024 | $1.1M | -$49.0M | $-0.71 |
| Q3 2023 | $42.0K | -$40.3M | $-0.55 |
| Q2 2023 | $2.9M | -$40.3M | $-0.56 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
EDIT Capital Allocation
EDIT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Editas Medicine, Inc. (CIK: 0001650664)
📋 Recent SEC Filings
❓ Frequently Asked Questions about EDIT
What is the AI rating for EDIT?
Editas Medicine, Inc. (EDIT) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are EDIT's key strengths?
Claude: Strong liquidity position with $146.6M in cash and 3.54x current ratio providing near-term operational flexibility. Revenue growth of 25.4% YoY shows commercial traction in their therapeutic programs.
What are the risks of investing in EDIT?
Claude: Unsustainable cash burn rate of -$165.8M in free cash flow with only ~11 months of cash runway at current burn rate. Pre-commercial or early-stage company with -$160M operating loss and -395% net margin indicating no path to profitability in near-term.
What is EDIT's revenue and growth?
Editas Medicine, Inc. reported revenue of $40.5M.
Does EDIT pay dividends?
Editas Medicine, Inc. does not currently pay dividends.
Where can I find EDIT SEC filings?
Official SEC filings for Editas Medicine, Inc. (CIK: 0001650664) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is EDIT's EPS?
Editas Medicine, Inc. has a diluted EPS of $-1.80.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is EDIT a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Editas Medicine, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is EDIT stock overvalued or undervalued?
Valuation metrics for EDIT: ROE of -586.6% (sector avg: 15%), net margin of -395.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy EDIT stock in 2026?
Our dual AI analysis gives Editas Medicine, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is EDIT's free cash flow?
Editas Medicine, Inc.'s operating cash flow is $-165.2M, with capital expenditures of $607.0K. FCF margin is -409.3%.
How does EDIT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -395.0% (avg: 12%), ROE -586.6% (avg: 15%), current ratio 3.54 (avg: 2).